1. Home
  2. LRMR
  3. Earnings

AI Earnings Predictions for Larimar Therapeutics Inc. (LRMR)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-3.90%

$2.44

0% positive prob.

5-Day Prediction

-7.25%

$2.35

0% positive prob.

20-Day Prediction

-0.28%

$2.53

0% positive prob.

Price at prediction: $2.54 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -3.90% -7.25% -0.28% 100.0% Pending
Q2 2026 BUY +7.59% +15.22% +13.95% 100.0% +4.87%
Q1 2026 SELL -3.50% -7.16% +0.77% 100.0% -8.23%
Q4 2025 SELL -4.16% -7.78% +0.59% 100.0% -1.54%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 9, 2026 · 100% conf.

AI Prediction SELL

1D

-3.90%

$2.44

Act: +7.11%

5D

-7.25%

$2.35

20D

-0.28%

$2.53

Price: $2.54 Prob +5D: 0% AUC: 1.000
0001193125-26-453586

EX-99.1

2 lrmr-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA

• Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint

• Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population

• Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp

Bala Cynwyd, PA, November 9, 2026 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich’s ataxia (FA). Nomlabofusp is an investigational protein replacement therapy designed to address the underlying cause of FA, frataxin deficiency, by delivering human frataxin to mitochondria.

Completion of the submission follows previously disclosed FDA feedback on key elements of the BLA and represents a significant milestone for Larimar. Larimar is currently enrolling patients in FORWARD-FA, its global confirmatory Phase 3 study, a double-blind, placebo-controlled study that will evaluate daily subcutaneous use of nomlabofusp over 18 months in ambulatory participants ages 2 to 40 who are new to the drug. Approximately two thirds of the participants will be under the age of 21.

“Completing our BLA submission is a major milestone for Larimar and the FA community, bringing years of development work together in an application seeking accelerated approval of nomlabofusp,” said Carole Ben-Maimon, MD, Chief Executive Officer of Larimar. “Our confidence in the program is grounded in the sustained increases in skin frataxin and consistent directional improvements observed in multiple clinical outcomes in patients. It is important to note that patients with FA are expected to experience continued neurologic decline, not improvement. After treatment with nomlabofusp, we have not observed worsening in most participants but rather signs of improvement. Our previously disclosed discussions with FDA have helped inform the content of the submission. As we support the potential FDA review and advance FORWARD-FA, our confirmatory Phase 3 study, our team is preparing for a potential U.S. launch with the goal of making nomlabofusp available to patients as quickly as possible following approval, if granted. In parallel, we continue to evaluate options to optimize our global commercialization strategy.”

The BLA seeks accelerated approval based on increases in skin frataxin (FXN) concentrations as a potential novel surrogate endpoint and is supported by data from the ongoing long-term open label (OL) study. Previously reported findings showed sustained increases in skin FXN, with all evaluable participants at one year achieving skin FXN levels within the range expected in asymptomatic heterozygous carriers. Directional improvements were observed at one year across multiple clinical outcomes relative to worsening in a natural history reference population. Directional improvement of exploratory pharmacodynamic markers (plasma lipids and peripheral tissue gene transcription) compared to placebo treated patients were also observed. Nomlabofusp has the potential to be the first disease-modifying therapy for patients with FA.

“Larimar’s completion of its BLA submission for nomlabofusp marks an important and exciting milestone for the Friedreich’s ataxia community. As the first potential frataxin replacement therapy, nomlabofusp is designed to address the underlying cause of FA. The fact that the submission includes data from adolescents ages 12 to 17 is especially meaningful, as there are currently no approved therapies for children under 16 years of age. FA is a complex and variable disease, and patients and families need multiple treatment options that can address their individual needs across different ages and stages of disease,” said Jen Farmer, M.S., Chief Executive Officer, Friedreich’s Ataxia Research Alliance (FARA).

Submission Highlights:

• Data Package Supporting Submission and Review: FDA reviewed OL study data submitted in a briefing package and confirmed in minutes from the multidisciplinary Type B pre-BLA meeting that the existing data package appears capable of supporting submission and review of a BLA seeking accelerated approval of nomlabofusp as a treatment for patients with FA. Approval will be

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 4, 2026 · 100% conf.

AI Prediction BUY

1D

+7.59%

$4.42

Act: -0.24%

5D

+15.22%

$4.74

Act: +4.87%

20D

+13.95%

$4.68

Price: $4.11 Prob +5D: 100% AUC: 1.000
0001193125-26-331516

EX-99.1

2 lrmr-ex99_1.htm

EX-99.1

EX-99.1

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

• Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures

• High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end

• Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026

• Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026

• $156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway into the third quarter of 2027

Bala Cynwyd, PA, August 4, 2026 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2026 operating and financial results.

“This is a defining period for Larimar as we advance nomlabofusp toward potential approval, supported by a clear path to submission, a robust data package, and continued clinical momentum,” said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar. “Open label (OL) study data announced in June further reinforce the disease-modifying potential of nomlabofusp, demonstrating continued directional improvements in key clinical endpoints over time alongside a well-characterized safety profile. Following receipt of minutes from a successful Type B multidisciplinary pre-BLA meeting with the Food and Drug Administration (FDA), the first module of our rolling Biologics License Application (BLA) has been submitted, with completion expected in the second half of 2026. We continue to see strong enthusiasm from patients and investigators as we advance the OL study with additional participants dosed in July and several adults and adolescents in screening. We are also on track to initiate dosing in our global confirmatory study this quarter. Looking ahead, we are focused on execution as we work to bring forward nomlabofusp as the first potential therapy to address the underlying cause of disease for pediatric and adult patients living with Friedreich’s ataxia (FA).”

Highlights

• June Open Label Study Data Release. As of June 2026, 43 adolescent and adult participants in the OL study received at least one dose of nomlabofusp and 22 participants remain in the study with a maximum treatment duration of more than 800 days. More than 10,000 doses of nomlabofusp have been administered.

o Consistent Long-term Safety Profile.

▪ Longer-term dosing was generally well tolerated with thirteen adults on treatment for one year, seven for 18 months and three for two years.

▪ The most common adverse events remained mild-to-moderate local injection site reactions, which decreased in frequency over time and did not lead to any withdrawals from the study.

▪ Twenty-one participants discontinued since study initiation in January 2024.

• Ten participants experienced anaphylaxis and discontinued the study, including nine participants with prior nomlabofusp exposure; all participants who experienced anaphylaxis responded to standard therapy and all returned to their usual state of health with no further sequelae.

• Three participants experienced generalized urticaria and discontinued the study, with no new occurrences observed following initiation of antihistamine therapy.

• Other discontinuations included three associated with other adverse events and five discontinuations unrelated to treatment, primarily due to logistical factors.

▪ Of the eleven participants who had previously not been exposed to nomlabofusp, one had anaphylaxis.

o Sustained Increases in Skin FXN Levels Comparable to Asymptomatic Carriers. Skin frataxin (FXN) levels increased following nomlabofusp administration, with 82% (9/11) of participants achieving levels above those in asymptomatic carriers by six months, 100% (9/9) reaching this threshold at one year, and 100% (3/3) maintaining it through 18 months.

o Improvements in Key Clinical Outcome Measures Relative to FACOMS Natural History Population.

▪ Directional improvement across key clinical endpoints, including mFARS, FARS-ADL, and 9-HPT1, was sustained following one year of nomlabofusp treatment (n=13) relative to a worsening in those outcomes observed in the Friedreich’s Ataxia Clinical Outcome Measures Study (FACOMS) reference population.

▪ Nomlabofusp led to a 2.6-point benefit in mFARS at one year.

▪ Improvement in clinical outcomes was associated with increased skin FXN levels, supporting the potential for nomlabofusp to provide clinical benefit across a broad spectrum of patients with FA, including those with advanced disease.

1Modified Friedreich Ataxia Rating

2026
Q1

Q1 2026 Earnings

8-K SELL

May 14, 2026 · 100% conf.

AI Prediction SELL

1D

-3.50%

$3.75

Act: -8.61%

5D

-7.16%

$3.61

Act: -8.23%

20D

+0.77%

$3.92

Act: -10.80%

Price: $3.89 Prob +5D: 0% AUC: 1.000
0001193125-26-222746

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784464118.eb3409f4

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

About Larimar Therapeutics Inc. (LRMR) Earnings

This page provides Larimar Therapeutics Inc. (LRMR) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on LRMR's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: